We claim:

1. A combination consisting of a pure 5-HT_6 receptor antagonist and an acetylcholinesterase inhibitor, wherein the pure 5-HT_6 receptor antagonist is selected from
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
or a pharmaceutically acceptable salt thereof.

2. The combination as claimed in claim 1, wherein the pure 5-HT_6 receptor antagonist is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1 or claim 2, wherein the pharmaceutically acceptable salt of the pure 5-HT_6 receptor antagonist is selected from
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride.

4. The combination as claimed in any one of the claims 1 to 3, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, galantamine and rivastigmine or a pharmaceutically acceptable salt thereof.

5. The combination as claimed in any one of the claims 1 to 4, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil and rivastigmine or a pharmaceutically acceptable salt thereof.

6. The combination as claimed in any one of the claims 1 to 5, wherein the acetylcholinesterase inhibitor or a pharmaceutically acceptable salt thereof is donepezil hydrochloride.

7. The combination as claimed in any one of the claims 1 to 6, for use in the treatment of cognitive disorders in a patient.

8. Use of the combination as claimed in any one of claims 1 to 6 in the manufacture of a medicament for the treatment of cognitive disorders in a patient, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia and frontotemporal dementia.

9. Use of a combination consisting of a compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient.

10. The use as claimed in claim 9, wherein the medicament is for an adjunct treatment in a patient on stable treatment with an acetylcholinesterase inhibitor.

11. The use as claimed in claim 9 or claim 10, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, galantamine and rivastigmine or a pharmaceutically acceptable salt thereof.

12. The use as claimed in any one of the claims 9 to 11, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil and rivastigmine or a pharmaceutically acceptable salt thereof.

13. The use as claimed in claim 9 or claim 10, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

14. The use as claimed in claim 9, (a) wherein 1 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(b) wherein 1 mg to 10 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(c) wherein 25 mg to 125 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(d) wherein 150 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(e) 25 mg to 75 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or pharmaceutically acceptable salt is to be administered to a patient per day, or
(f) 75 mg to 150 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day; and
(g) wherein 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(h) wherein 5 mg to 25 mg of donepezil or a pharmaceutically acceptable salt thereof is to be administered to the patient per day, or
(i) wherein 10 mg to 25 mg donepezil or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

15. A pharmaceutical composition comprising the combination as claimed in any one of claims 1 to 6, and pharmaceutically acceptable excipients.

16. The pharmaceutical composition as claimed in claim 15, for use in the treatment of cognitive disorders selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia and frontotemporal dementia.

17. The pharmaceutical composition as claimed in claim 15 or the pharmaceutical composition for use as claimed in claim 16, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present
(a) in an amount of 1 mg to 300 mg, or
(b) in an amount of 35 mg to 200 mg, or
(c) in an amount of 200 mg to 300 mg, or
(d) in an amount of 75 mg to 150 mg.

18. The pharmaceutical composition as claimed in claim 15 or the pharmaceutical composition for use as claimed in claim 16, wherein the donepezil or a pharmaceutically acceptable salt thereof is present;
(a) in an amount of 2 mg to 30 mg, or
(b) in an amount of 5 mg to 25 mg, or
(c) in an amount of 5 mg, or
(d) in an amount of 10 mg, or
(e) in an amount of 23 mg.

19. The use as claimed in claim 9, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

20. The use as claimed in claim 9, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.

21. Use of a combination as claimed in any one of claims 1 to 8; or of a combination consisting of a compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor or a pharmaceutically acceptable salt thereof; or of a pharmaceutical composition comprising the combination as claimed in any one of claims 1

to 8 and pharmaceutically acceptable excipients in the manufacture of a medicament for the treatment of cognitive disorders.